Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
Loxo Oncology, Inc. (LOXO) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/15/2019 8-K Quarterly results
01/07/2019 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 5, 2019 LOXO ONCOLOGY, INC. Delaware 001-36562 46-2996673 281 Tresser Blvd., 9th Floor Stamford, CT 06901 653-3880 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 und...",
"Agreement and Plan of Merger, by and among Eli Lilly and Company, Bowfin Acquisition Corporation and Loxo Oncology, Inc",
"Tender and Support Agreement, by and among Eli Lilly and Company, Bowfin Acquisition Corporation and Aisling Capital III, LP",
"Lilly Announces Agreement To Acquire Loxo Oncology"
01/02/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/06/2018 8-K Regulation FD Disclosure
11/27/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Bayer to Provide Comprehensive Value and Access Programs"
11/08/2018 8-K Quarterly results
Docs: "Loxo Oncology Reports Third Quarter 2018 Financial Results",
"Corporate Presentation"
09/17/2018 8-K Other Events
08/09/2018 8-K Quarterly results
Docs: "Loxo Oncology Reports Second Quarter 2018 Financial Results"
06/14/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/04/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual Meeting",
"Slides presented by Loxo Oncology on June 2, 2018"
05/08/2018 8-K Quarterly results
Docs: "Loxo Oncology Reports First Quarter 2018 Financial Results"
03/01/2018 8-K Quarterly results
Docs: "Loxo Oncology Reports Fourth Quarter and Year-End 2017 Financial Results"
02/21/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Central Assessment Investigator Assessment Overall response rate 75% 80% Partial response 62% 64%* Complete response 13% 16% Stable disease 13% 9% Progressive disease 9% 11% Could not be evaluated 4% 0"
01/08/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Corporate Presentation"
12/27/2017 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/04/2017 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers"
11/21/2017 8-K Entry into a Material Definitive Agreement
11/14/2017 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195"
11/02/2017 8-K Quarterly results
Docs: "Loxo Oncology Announces Third Quarter 2017 Financial Results"
10/18/2017 8-K Quarterly results
10/18/2017 8-K Quarterly results
09/28/2017 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Loxo Oncology Announces Details of LOXO-292 Abstract to be Presented as Late-Breaking Presentation at the IASLC 18th World Conference on Lung Cancer STAMFORD, Conn., Sept 27, 2017 — Loxo Oncology, Inc. , a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced details of the LOXO-292 abstract that will be presented as a late-breaking oral presentation at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer being held from October 15-18, 2017, in Yokohama, Japan. LOXO-292 is Loxo Oncology's highly selective RET inhibitor. The abstract describes the first two patients with RET-fusion lung cancer with and without brain metastases treated with LOXO-292. Both patients ...",
"Abstract accepted for presentation at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer"
08/08/2017 8-K Quarterly results
Docs: "Loxo Oncology Announces Second Quarter 2017 Financial Results"
07/31/2017 8-K Form 8-K - Current report:
06/23/2017 8-K Form 8-K - Current report
06/15/2017 8-K Form 8-K - Current report
06/05/2017 8-K Form 8-K - Current report
05/09/2017 8-K Form 8-K - Current report
03/21/2017 8-K Form 8-K - Current report
03/07/2017 8-K Form 8-K - Current report
01/05/2017 8-K Form 8-K - Current report
12/19/2016 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
11/02/2016 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy